Compare OPTU & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPTU | RGNX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.5M | 761.9M |
| IPO Year | N/A | 2015 |
| Metric | OPTU | RGNX |
|---|---|---|
| Price | $1.41 | $8.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $2.00 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 1.7M | 753.6K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | $58.79 |
| Revenue Next Year | N/A | $29.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $1.33 | $5.04 |
| 52 Week High | $2.14 | $16.19 |
| Indicator | OPTU | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 44.43 |
| Support Level | $1.38 | $7.83 |
| Resistance Level | $1.58 | $9.28 |
| Average True Range (ATR) | 0.09 | 0.60 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 30.00 | 32.77 |
Optimum Communications Inc acquired privately held US cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and businesses in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.